uniqure logo

 

Dear Huntington’s Disease Community Members,

This morning, uniQure issued a press release which included an update on our clinical trial of AMT-130 (the name of the study drug) for Huntington’s Disease (HD.) After a brief pause announced this past August in patient enrollment at the higher-dose level in the European Phase I/II clinical trial of AMT-130, the trial’s Data Safety Monitoring Board (DSMB) has recommended that patient enrollment resume at this higher dose. This means that the independent group of expert HD physicians looked at all of the information available to them and deemed the risk-benefit of AMT-130 worthy of proceeding.

CLICK HERE FOR FULL STATEMENT FROM UNIQURE